Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersJeffrey A. Engelman, Kwok‐Kin Wong, Alexander R. Guimarães et al.|Nature Medicine|2008Cited by 1.3k
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancerMartin L. Sos, Roman K. Thomas, Stefanie Fischer et al.|Proceedings of the National Academy of Sciences|2009Cited by 255